Found 32 articles
Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview
The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.
Financing will support the clinical development of Prokarium’s microbial immunotherapy for non-muscle invasive bladder cancer as well as expansion of pipeline across multiple solid tumours
Sesen Bio Announces Successful Pre-Submission Meeting with the European Medicines Agency for Vicineum™
Meeting outcome confirms the Company’s pathway to a planned MAA submission for Vicineum in early 2021 with anticipated approval in early 2022
The pharma giant is currently the only manufacturer of the bladder cancer treatment for the U.S. and Europe.
Serum Institute of India Initiates Manufacturing of Codagenix's Intranasal Live-Attenuated COVID-19 Vaccine Candidate
- Phase 1 clinical trial of CDX-005 expected to initiate prior to year-end 2020 - Serum Institute to ramp-up manufacturing for large-scale safety and efficacy studies and to meet global vaccine supply requirements [22-September-2020] FARMINGDALE, N.Y. , Sept. 22, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing pr
Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications
Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs
Codagenix Announces the Synthesis and Preliminary Safety of Scalable, Live-attenuated Vaccine Candidate Against COVID-19
Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the successful synthesis of a readily-scalable live-attenuated vaccine candidate against COVID-19. The vaccine, CDX-005, is currently undergoing safety and efficacy studies in animals and appears m
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 12, 2020.
Prokarium Signs an Exclusive Option Agreement with the Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois - CHUV) for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
Prokarium is pleased to announce it has signed an exclusive, worldwide Option Agreement with the Lausanne University Hospital - CHUV, a Switzerland-based research hospital, to acquire a license to cover the treatment of Non-Muscle Invasive Bladder Cancer patients with intravesical instillations of Salmonella.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.
Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19
FARMINGDALE, N.Y. , Feb. 13, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. There are no licensed vaccines or therapeutics for this nov
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on December 6, 2019, the Company initiated the submission of its Biologics License Application (BLA) for Vicinium for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) under Rolling Review to the U.S. Food and Drug Administration (FDA).
Alignment reached with FDA on post-marketing confirmatory trial design
Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology
Aridis Pharmaceuticals, Inc. announced that it has consummated a licensing agreement with Serum AMR, an affiliate of Serum International BV and the Serum Institute of India, Ltd.
Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Sesen Bio reported updated, preliminary primary and secondary endpoint data from the Company’s Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicinium for the potential treatment of patients with high-risk, bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer.
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology
Aridis Pharmaceuticals, Inc. announced that it has entered into an option agreement with the Serum International BV, an affiliate of Serum Institute of India, Ltd., the world's largest vaccine manufacturer by dose units.
Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Sesen Bio reported operating results for the first quarter ended March 31, 2019.
The American Urological Association (AUA) and the Urology Care Foundation—the official foundation of the AUA—are pleased to announce the recipients of the 2019 Urology Care Foundation Research Scholar Awards.
IAVI and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products for HIV
Collaboration to develop optimal combination of HIV-specific antibodies and ensure that cost is not a barrier to access